pDx App by electronRx Set to Advance Remote Monitoring for Respiratory Patients

Published: 19 Sep 2025

Author: Precedence Research

Share :

electronRx, a global digital medicine and biomarker developer whose core business is pulmonary innovation, has announced a plan to debut its innovative pDx platform at HLTH 2025. The idea behind the new solution is to transform the management of chronic respiratory diseases (CRDs). This allows patients to test their lung function and cardiopulmonary health from the comfort of their own homes using only a mobile phone, laptop, or tablet. pDx enables better diagnosis, monitoring of disease progression, and making personalised treatment adaptations.

PDX was constructed to medical-grade standards, and the platform represents a key breakthrough in remote respiratory monitoring. This technology minimizes reliance on hospital visits, which puts a strain on the already overstretched healthcare systems. pDx offers clinicians the appropriate tools to enhance the therapeutic outcome and assist the patients in gaining more independence and peace of mind, managing diseases, including asthma, COPD, interstitial lung disease, and pulmonary hypertension, by providing clinicians with reliable, constant data via a secure clinical dashboard. The pDx solution is a development of the proprietary purpleDx technology of electronRx, which uses the sensors on a smartphone to measure cardiopulmonary activity.

As the digital health and remote monitoring sectors are growing exponentially, the pDx platform enters the market at the right time with electronRX. Clinicians around the world are keen on finding instruments that will enhance clinical outcomes, reduce costs, and expand accessibility. Digital biomarkers, including those produced by pDx, are being viewed as the future of precision medicine, which can provide a more detailed insight into disease conditions and provide real-time feedback on therapeutic effectiveness.

The introduction of pDx makes electronRx a leader in the integration of respiratory medicine, AI-assisted generation of biomarkers, and digital therapeutics. Furthermore, through its demonstration at HLTH 2025, one of the leading healthcare innovation conferences worldwide, electronRx is able to emphasize how its solutions can lead to the next generation of connected, patient-centered care.

Executive's Statement:

Dr. Bipin Patel, CEO and Founder of electronRx:

“electronRx is dedicated to transforming the lives of people living with breathing disorders. pDx represents a major step forward in personalised respiratory care, and we very much look forward to demonstrating the technology at HLTH. The platform's scalable architecture supports integration into existing care pathways, allowing for proactive intervention and reduced reliance on in-person visits. By facilitating continuous monitoring, pDx helps clinicians personalise care while improving patient adherence and reducing healthcare burden. Most importantly, it gives patients greater flexibility and control over their healthcare journey."